LYNPARZA (olaparib)
ANTINEOPLASTIC-POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITOR · EPITHELIAL OVARIAN CANCER ·+5
AstraZeneca Pharmaceuticals
Drug class
Antineoplastic-Poly (ADP-Ribose) polymerase (PARP) inhibitor
Antineoplastic poly (ADP-ribose) polymerase (PARP) inhibitors are a class of targeted oncology agents that block PARP enzymes responsible for repairing single-strand DNA breaks. Read more about Antineoplastic-Poly (ADP-Ribose) polymerase (PARP) inhibitor
6 drugs in this class 6 manufacturers
Drugs in Antineoplastic-Poly (ADP-Ribose) polymerase (PARP) inhibitor
TALZENNA (talazoparib tosylate)
ANTINEOPLASTIC-POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITOR · METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WITH HRR GENE MUTATION ·+1
Parke-Davis Pfizer
ZEJULA (niraparib tosylate)
ANTINEOPLASTIC-POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITOR · EPITHELIAL OVARIAN CANCER WITH BRCA MUTATION ·+1
GSK
AKEEGA (niraparib tosylate/abiraterone acetate)
ANTINEOPLASTIC-POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITOR · METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WITH BRCA MUTATION ·+1
JANSSEN BIOTECH, Inc.
TALZENNA (talazoparib tosylate)
ANTINEOPLASTIC-POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITOR · METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WITH HRR GENE MUTATION ·+1
Laboratories Div
RUBRACA (rucaparib camsylate)
ANTINEOPLASTIC-POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITOR · EPITHELIAL OVARIAN CANCER WITH BRCA MUTATION ·+1
ZR PHARMA& GMBH
Filter & compare in the drug finder →
Opens the drug finder with Antineoplastic-Poly (ADP-Ribose) polymerase (PARP) inhibitor preselected. Add indication or manufacturer filters there.
Antineoplastic poly (ADP-ribose) polymerase (PARP) inhibitors are a class of targeted oncology agents that block PARP enzymes responsible for repairing single-strand DNA breaks.
By inhibiting PARP catalytic activity and trapping the enzyme on damaged DNA, these drugs cause single-strand breaks to progress into lethal double-strand breaks during replication.
This mechanism exploits synthetic lethality, preferentially killing tumor cells with preexisting homologous recombination repair deficiencies, such as BRCA gene mutations.
Clinically, PARP inhibitors are widely approved as monotherapy or combination therapy for the treatment and maintenance of ovarian, breast, prostate, and pancreatic cancers bearing relevant DNA repair defects.
-
fda.gov
Antineoplastic poly (ADP-ribose) polymerase (PARP) inhibitors are a class of targeted oncology agents that block PARP enzymes responsible for repairing single-strand DNA breaks By inhibiting PARP catalytic activity and trapping the enzyme on damaged DNA, these drugs cause single-strand breaks to progress into lethal double-strand breaks during replication This mechanism exploits synthetic lethality, preferentially killing tumor cells with preexisting homologous recombination repair deficiencies,...
-
cancer.gov
Antineoplastic poly (ADP-ribose) polymerase (PARP) inhibitors are a class of targeted oncology agents that block PARP enzymes responsible for repairing single-strand DNA breaks By inhibiting PARP catalytic activity and trapping the enzyme on damaged DNA, these drugs cause single-strand breaks to progress into lethal double-strand breaks during replication
-
cancer.gov
Antineoplastic poly (ADP-ribose) polymerase (PARP) inhibitors are a class of targeted oncology agents that block PARP enzymes responsible for repairing single-strand DNA breaks
-
cancer.gov
This mechanism exploits synthetic lethality, preferentially killing tumor cells with preexisting homologous recombination repair deficiencies, such as BRCA gene mutations Clinically, PARP inhibitors are widely approved as monotherapy or combination therapy for the treatment and maintenance of ovarian, breast, prostate, and pancreatic cancers bearing relevant DNA repair defects
-
fda.gov
Clinically, PARP inhibitors are widely approved as monotherapy or combination therapy for the treatment and maintenance of ovarian, breast, prostate, and pancreatic cancers bearing relevant DNA repair defects
-
fda.gov
Clinically, PARP inhibitors are widely approved as monotherapy or combination therapy for the treatment and maintenance of ovarian, breast, prostate, and pancreatic cancers bearing relevant DNA repair defects
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.